DDInter1652 DDInter1315
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
Norgestrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pioglitazone
Norgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linaclotide
Norgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Norgestrel {u} may lead to a major life threatening interaction when taken with {v} Griseofulvin
Norgestrel {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Norgestrel may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Norgestrel may lead to a major life threatening interaction when taken with Griseofulvin
Norgestrel may lead to a major life threatening interaction when taken with Encorafenib